Evotec SE American Depositary Shares
EVO Real Time Price USDRecent trades of EVO by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by EVO's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
EVO Revenue by Segment or Geography
New patents grants
-
Patent Title: Modulators of the integrated stress response pathway Mar. 25, 2025
-
Patent Title: Non-invasive, in vitro functional tissue assay systems Dec. 05, 2023
-
Patent Title: Treatment of sleep disorders Aug. 06, 2019
-
Patent Title: Sulfoximine substituted quinazolines for pharmaceutical compositions Jan. 01, 2019
-
Patent Title: Method for detecting the impacts of interfering effects on experimental data Sep. 12, 2017
-
Patent Title: Sulfoximine substituted quinazolines for pharmaceutical compositions Jul. 18, 2017
-
Patent Title: Markers for susceptibility to an inhibitor of an src-family kinase May. 03, 2016
-
Patent Title: Amide compounds, compositions and uses thereof Sep. 15, 2015
-
Patent Title: Screening methods for compounds useful for treating pancreatic dysfunction Jun. 09, 2015
-
Patent Title: Neurturin conjugates for pharmaceutical use May. 12, 2015
-
Patent Title: Amide compounds, compositions and uses thereof Feb. 03, 2015
-
Patent Title: Azetidines as histamine h3 receptor antagonists Dec. 16, 2014
-
Patent Title: Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful for the treatment of inflammatory and respiratory diseases Oct. 14, 2014
-
Patent Title: Bicycloheteroaryl compounds as p2x7 modulators and uses thereof Jul. 15, 2014
-
Patent Title: Method for promoting regeneration of pancreatic beta-cells by administering neurturin Jul. 08, 2014
-
Patent Title: Azetidines and cyclobutanes as histamine h3 receptor antagonists Apr. 08, 2014
-
Patent Title: Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof Feb. 18, 2014
-
Patent Title: Bradykinin b1 antagonists Jan. 07, 2014
-
Patent Title: Method for detecting an analyte in a sample Nov. 12, 2013
-
Patent Title: Ppm1e proteins and nucleic acids as targets for neurodegenerative diseases Nov. 05, 2013
-
Patent Title: Method for analyzing chemical and/or biological samples by means of particle images Oct. 22, 2013
-
Patent Title: Bicycloheteroaryl compounds as p2x Oct. 01, 2013
-
Patent Title: Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome Aug. 06, 2013
-
Patent Title: Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same Apr. 24, 2012
-
Patent Title: Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same Apr. 10, 2012
-
Patent Title: 2-cyanophenyl-7,8-dihydro-5h-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof Dec. 13, 2011
-
Patent Title: Device and method for examining chemical and/or biological samples, and objective cap Jun. 14, 2011
-
Patent Title: Method for detecting geometrical structures in images Mar. 08, 2011
-
Patent Title: Method for detecting analytes in a sample Jan. 11, 2011
-
Patent Title: Climate chamber for microscopes Aug. 03, 2010
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to EVO
Recent picks made for EVO stock on CNBC
ETFs with the largest estimated holdings in EVO
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $EVO stock a Buy, Sell, or Hold?
- What is the price target for $EVO stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $EVO stock?
- Who owns the most shares of $EVO stock?
- What funds own $EVO stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view EVO Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.